<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN"
"http://www.w3.org/TR/REC-html40/loose.dtd"> 
<html>
<head>
<title>Untitled Document</title>
<meta http-equiv="Content-Type" content="text/html;charset=utf-8">
</head>
<body>
<p>

# en/1.xml.gz<br>
# mt/1.xml.gz

<p><hr>
(src)="1"> its purity ; <br>
(trg)="1"> il - purità tiegħu ; <br>
<hr>
(src)="2"> Are there serious side effects ? <br>
(trg)="2"> Hemm effetti sekondarji serji ? <br>
<hr>
(src)="3"> Thousands of volunteers <br>
(trg)="3"> Eluf ta ' voluntiera <br>
<hr>
(src)="4"> its ingredients , including its inactive ingredients or ‘ excipients ' ; <br>
(trg)="4"> l - ingredjenti tiegħu , inkluż l - ingredjenti mhux attivi tiegħu jew l - " eċċipjenti " ; <br>
<hr>
(src)="5"> Does the vaccine seem to work ? <br>
(trg)="5"> Il - vaċċin huwa sikur ? <br>
<hr>
(src)="6"> How are the immune systems of the participants responding to the vaccine ? <br>
(trg)="6"> Is - sistemi immuni tal - parteċipanti kif jirrispondu għall - vaċċin ? <br>
<hr>
(src)="7"> This involves tests in the laboratory and in animals . <br>
(trg)="7"> Dan jinvolvi testijiet fil - laboratorju u fl - annimali . <br>
<hr>
(src)="8"> These include the European Medicines Agency and other regulators in the EU / EEA countries . <br>
(trg)="8"> Dawn jinkludu l - Aġenzija Ewropea għall - Mediċini u regolaturi oħrajn fil - pajjiżi tal - UE / taż - ŻEE . <br>
<hr>
(src)="9"> At the end of the testing programme , the vaccine developer submits the results to the medicines regulatory authorities in Europe as part of a ‘ marketing authorisation ' application . <br>
(trg)="9"> Fl - aħħar tal - programm ta ' ttestjar , l - iżviluppatur tal - vaċċin jissottometti r - riżultati lill - awtoritajiet regolatorji tal - mediċini fl - Ewropa bħala parti minn applikazzjoni ta ' " awtorizzazzjoni għat - tqegħid fis - suq " . <br>
<hr>
(src)="10"> This is followed by a clinical testing programme in humans , which can take around ten years from initial concept to authorisation and must adhere to strict standards . <br>
(trg)="10"> Dan jiġi segwit minn programm ta ' ttestjar kliniku fil - bnedmin , li jista ' jieħu sa għaxar snin mill - kunċett inizjali sal - awtorizzazzjoni u għandu jaderixxi ma ' standards stretti . <br>
<hr>
(src)="11"> What are the most common side effects ? <br>
(trg)="11"> Liema huma l - effetti sekondarji l - aktar komuni ? <br>
<hr>
(src)="12"> Medicines regulatory authorities can carry out inspections to make sure that the information the vaccine developer provides is trustworthy . <br>
(trg)="12"> L - awtoritajiet regolatorji tal - mediċini jistgħu jagħmlu spezzjonijiet biex jiżguraw li l - informazzjoni li jipprovdi l - iżviluppatur tal - vaċċin hija ta ' min joqgħod fuqha . <br>
<hr>
(src)="13"> The companies are required to conduct stringent testing , for which the acceptance criteria are pre-defined by the authorities , on each batch of vaccine released onto the EU market . <br>
(trg)="13"> Il - kumpaniji huma meħtieġa jwettqu ttestjar strinġenti , li għalih , il - kriterji tal - aċċettazzjoni tiegħu jiġu definiti minn qabel mill - awtoritajiet , fuq kull lott ta ' vaċċini rilaxxat fis - suq tal - UE . <br>
<hr>
(src)="14"> This programme has to follow the procedures and protocols set by the regulators : <br>
(trg)="14"> Dan il - programm għandu jsegwi l - proċeduri u l - protokolli stabbiliti mir - regolaturi : <br>
<hr>
(src)="15"> how it is manufactured . <br>
(trg)="15"> kif jiġi manifatturat . <br>
<hr>
(src)="16"> Before a vaccine can be approved in the EU , it has to undergo rigorous testing by its developer and then scientific evaluation by regulatory authorities . <br>
(trg)="16"> Qabel ma vaċċin ikun jista ' jiġi approvat fl - UE , irid jgħaddi minn ittestjar rigoruż mill - iżviluppatur tiegħu , u mbagħad minn evalwazzjoni xjentifika mill - awtoritajiet regolatorji . <br>
<hr>
(src)="17"> Twitter Facebook Linked In Mail <br>
(trg)="17"> Benefiċċji tat - tlaqqim <br>
<hr>
(src)="18"> Testing includes checking the vaccine 's quality : <br>
(trg)="18"> L - ittestjar jinkludi li tiġi ċċekkjata l - kwalità tal - vaċċin : <br>
<hr>
(src)="19"> The vaccine developer tests the vaccine in three phases of clinical trials , with larger numbers of people in each phase . <br>
(trg)="19"> L - iżviluppatur tal - vaċċin jittestja l - vaċċin fi tliet fażijiet ta ' provi kliniċi , b'numri akbar ta ' persuni f'kull fażi . <br>
<hr>
(src)="20"> The regulators can only approve the vaccine if its scientific evaluation of the tests results show that the vaccine 's benefits are greater than its risks . <br>
(trg)="20"> Ir - regolaturi jistgħu japprovaw il - vaċċin biss jekk l - evalwazzjoni xjentifika tar - riżultati tat - testijiet tiegħu turi li l - benefiċċji tal - vaċċin huma akbar mir - riskji tiegħu . <br>
<hr>
(src)="21"> Benefits of vaccinating <br>
(trg)="21"> Approvazzjoni tal - vaċċini fl - Unjoni Ewropea <br>
<hr>
(src)="22"> Then the vaccine developer tests the vaccine 's effects . <br>
(trg)="22"> Imbagħad l - iżviluppatur tal - vaċċin jittestja l - effetti tal - vaċċin . <br>
<hr>
(src)="23"> What is the optimal dose ? <br>
(trg)="23"> X'inhi l - aħjar doża ? <br>
<hr>
(src)="24"> They can also run tests to make sure that the batches of vaccines released onto the market are of the expected quality and have been manufactured correctly . <br>
(trg)="24"> Dawn jistgħu wkoll jagħmlu testijiet biex jiżguraw li l - lottijiet tal - vaċċini rilaxxati fis - suq ikunu tal - kwalità mistennija u jkunu ġew manifatturati kif suppost . <br>
<hr>
(src)="25"> Is the vaccine safe ? <br>
(trg)="25"> Il - vaċċin jidher li qed jaħdem ? <br>
<hr>
(src)="26"> Vaccination is the only way to ensure direct protection against tetanus . <br>
(trg)="26"> It - tilqim huwa l - uniku mod li jiżgura protezzjoni diretta kontra t - tetnu . <br>
<hr>
(src)="27"> For example , to ensure community immunity against measles , public health authorities recommend that 95 % of the population are vaccinated with two doses of the vaccine against measles ( the MMR vaccine , which protects against measles , mumps and rubella ) . <br>
(trg)="27"> Pereżempju , biex jiżguraw l - immunità komunitarja kontra l - ħosba , l - awtoritajiet tas - saħħa pubblika jirrakkomandaw li 95 % tal - popolazzjoni jitlaqqmu b'żewġ dożi tal - vaċċin kontra l - ħosba ( il - vaċċin MMR , li jipproteġi kontra l - ħosba , il - gattone u r - rubella ) . <br>
<hr>
(src)="28"> Vaccination protects the vaccinated persons and those around them who are vulnerable to the diseases , reducing the risk of diseases spreading among family members , school mates or colleagues , friends , neighbours and other people in the community . <br>
(trg)="28"> It - tilqim jipproteġi lill - persuni mlaqqma u lill - persuni ta ' madwarhom li huma vulnerabbli għall - mard , inaqqas ir - riskju li l - mard jinfirex fost il - membri tal - familja , ħbieb tal - iskola , kollegi , ħbieb , ġirien u persuni oħrajn fil - komunità . <br>
<hr>
(src)="29"> This is known as ' community immunity ' ( also referred to as ' herd immunity ' ) . <br>
(trg)="29"> Din hija magħrufa bħala " immunità komunitarja " ( li tissejjaħ ukoll " immunità bħala grupp " ) . <br>
<hr>
(src)="30"> Furthermore , immunisation programmes help reduce the social , psychological and financial burdens of disease on people and governments , reducing pressures on healthcare and social care systems and enabling people to pursue productive activities including education and employment . <br>
(trg)="30"> Barra minn hekk , il - programmi tal - immunizzazzjoni jgħinu biex inaqqsu l - piżijiet soċjali , psikoloġiċi u finanzjarji tal - mard fuq in - nies u l - gvernijiet , inaqqsu l - pressjonijiet fuq is - sistemi tal - kura tas - saħħa u tal - kura soċjali u jippermettu lin - nies iwettqu attivitajiet produttivi li jinkludu l - edukazzjoni u l - impjieg . <br>
<hr>
(src)="31"> Community immunity occurs when enough people in a population are immune to an infectious disease <br>
(trg)="31"> L - immunità komunitarja sseħħ meta biżżejjed persuni f'popolazzjoni jkunu immuni għal marda infettiva . <br>
<hr>
(src)="32"> However , people cannot rely on community immunity for some infectious diseases . <br>
(trg)="32"> Madankollu , in - nies ma jistgħux jiddependu fuq l - immunità komunitarja għal xi mard infettiv . <br>
<hr>
(src)="33"> For example , tetanus can be encountered due to common injuries , including dog or cat bites . <br>
(trg)="33"> Pereżempju , it - tetnu jista ' jittieħed minħabba korrimenti komuni , inkluż gdim tal - klieb jew tal - qtates . <br>
<hr>
(src)="34"> Benefits of vaccination for the community <br>
(trg)="34"> Il - benefiċċji tat - tilqim għall - komunità <br>
<hr>
(src)="35"> Benefits of vaccination for individuals <br>
(trg)="35"> Benefiċċji tat - tilqim għall - individwi <br>
<hr>
(src)="36"> These include babies , children , the elderly , people with weak immune systems , cancer patients , and people who cannot be vaccinated for medical reasons . <br>
(trg)="36"> Dawn jinkludu t - trabi , it - tfal , l - anzjani , il - persuni b'sistemi immunitarja dgħajfa , pazjenti bil - kanċer , u persuni li ma jistgħux jitlaqqmu minħabba raġunijiet mediċi . <br>
<hr>
(src)="37"> In this way , vaccines indirectly protect others who are vulnerable to disease . <br>
(trg)="37"> B'dan il - mod , il - vaċċini b'mod indirett jipproteġu lill - persuni l - oħra li jkunu vulnerabbli għall - marda . <br>
<hr>
(src)="38"> red rash ; <br>
(trg)="38"> raxx aħmar ; <br>
<hr>
(src)="39"> Up to 50 % of people infected with rubella do not experience symptoms . <br>
(trg)="39"> Sa 50 % tal - persuni infettati bir - rubella ma jesperjenzawx sintomi . <br>
<hr>
(src)="40"> The MMR ( measles , mumps and rubella ) vaccine is a combination vaccine that protects against measles , mumps and rubella . <br>
(trg)="40"> Il - vaċċin MMR ( il - ħosba , il - gattone u r - rubella ) huwa vaċċin ikkombinat li jipproteġi kontra l - ħosba , il - gattone u r - rubella . <br>
<hr>
(src)="41"> Rubella ( German measles ) is a viral infection . <br>
(trg)="41"> Ir - Rubella ( il - ħosba Ġermaniża ) hija infezzjoni virali . <br>
<hr>
(src)="42"> pain and inflammation of the joints in adults . <br>
(trg)="42"> uġigħ u infjammazzjoni tal - ġogi fl - adulti . <br>
<hr>
(src)="43"> What are the symptoms of rubella ? <br>
(trg)="43"> X'inhuma s - sintomi tar - rubella ? <br>
<hr>
(src)="44"> Who is at risk of rubella ? <br>
(trg)="44"> Min qiegħed f'riskju li taqbdu r - rubella ? <br>
<hr>
(src)="45"> The rubella virus is spread via airborne droplets produced when the infected person coughs and sneezes . <br>
(trg)="45"> Il - virus tar - rubella jinfirex minn taqtiriet fl - arja li jiġu prodotti meta l - persuna infettata tisgħol u tagħtas . <br>
<hr>
(src)="46"> What is rubella ? <br>
(trg)="46"> X'inhi r - rubella ? <br>
<hr>
(src)="47"> The MMR vaccine is safe and effective and has very few side effects . <br>
(trg)="47"> Il - vaċċin MMR huwa sikur u effikaċi u ma tantx għandu effetti sekondarji . <br>
<hr>
(src)="48"> The consequences for unvaccinated pregnant women that get rubella are particularly severe , due to the likelihood that contracting the disease during pregnancy can lead to miscarriage or CRS in their babies . <br>
(trg)="48"> Il - konsegwenzi għan - nisa tqal li mhumiex imlaqqma li taqbadhom ir - rubella huma partikolarment severi , probabbli minħabba l - fatt li l - marda waqt it - tqala tista ' twassal għal korriment jew CRS fit - trabi tagħhom . <br>
<hr>
(src)="49"> The only protection against rubella is vaccination . <br>
(trg)="49"> L - unika protezzjoni kontra r - rubella hija t - tilqim . <br>
<hr>
(src)="50"> Some vaccine recipients develop a non-infectious mild measles-like rash , typically 7-14 days after vaccination , which disappears within 1-3 days . <br>
(trg)="50"> Xi reċipjenti tal - vaċċin jiżviluppaw raxx ħafif mhux infettiv li jixbah lill - ħosba , tipikament bejn sebat ijiem u 14 - il jum wara t - tilqima , li jisparixxi bejn jum u tlett ijiem wara . <br>
<hr>
(src)="51"> However , if a woman gets rubella during the first three months of pregnancy , it is very likely to result in miscarriage or a baby born with congenital anomalies known as congenital rubella syndrome ( CRS ) . <br>
(trg)="51"> Madankollu , jekk mara taqbadha r - rubella matul l - ewwel tliet xhur tat - tqala , x'aktarx li tirriżulta f'korriment jew f'tarbija li titwieled b'disturbi konġenitali magħrufa bħala sindrome tar - rubella konġenitali ( CRS ) . <br>
<hr>
(src)="52"> swollen lymph glands around the ears and the back of the head ; <br>
(trg)="52"> għoqiedi limfatiċi minfuħa madwar il - widnejn u f'wara tar - ras ; <br>
<hr>
(src)="53"> Women who plan to become pregnant should check their vaccination status , as they cannot be vaccinated against rubella during pregnancy . <br>
(trg)="53"> In - nisa li beħsiebhom joħorġu tqal għandhom jivverifikaw l - istatus ta ' tilqim tagħhom , peress li ma jistgħux jitlaqqmu kontra r - rubella matul it - tqala . <br>
<hr>
(src)="54"> In healthy individuals it is usually a mild disease . <br>
(trg)="54"> F'individwi b'saħħithom din normalment tkun marda ħafifa . <br>
<hr>
(src)="55"> Anyone who has not had the disease or who has not been vaccinated with the MMR vaccine is at risk of contracting rubella . <br>
(trg)="55"> Kull min għadha ma qabditux il - marda jew min ma kienx imlaqqam bil - vaċċin MMR qiegħed f'riskju li taqbdu r - rubella . <br>
<hr>
(src)="56"> What are the complications of rubella ? <br>
(trg)="56"> Kif tiġi kkurata r - rubella ? <br>
<hr>
(src)="57"> CRS can lead to deafness , cataracts and learning disabilities in the baby . <br>
(trg)="57"> Is - CRS tista ' twassal għal truxija , katarretti u diżabilitajiet fit - tagħlim fit - tarbija . <br>
<hr>
(src)="58"> When symptoms do occur , they include : <br>
(trg)="58"> Meta s - sintomi jidhru , dawn jikludu : <br>
<hr>
(src)="59"> Two doses of the vaccine are needed for maximum protection . <br>
(trg)="59"> Għall - protezzjoni massima huma meħtieġa żewġ dożi tal - vaċċin . <br>
<hr>
(src)="60"> How is rubella treated ? <br>
(trg)="60"> Kif tista ' tiġi pprevenuta r - rubella ? <br>
<hr>
(src)="61"> European Vaccination Information Portal <br>
(trg)="61"> Portal Ewropew ta ' Informazzjoni dwar it - Tilqim <br>
<hr>
(src)="62"> In Europe , influenza occurs ... <br>
(trg)="62"> Fl - Ewropa , l - influwenza sseħħ . . . <br>
<hr>
(src)="63"> Influenza ( flu ) is a contagious respiratory illness caused by infection with an influenza virus . <br>
(trg)="63"> L - influwenza hija marda respiratorja li tittieħed ikkawżata minn infezzjoni b'virus tal - influwenza . <br>
<hr>
(src)="64"> Each virus and bacterium triggers a unique response in the immune system involving a specific set of cells in the blood ... <br>
(trg)="64"> Kull virus u batterju joħloq reazzjoni unika fis - sistema immunitarja li tinvolvi sett speċifiku ta ' ċelloli fid - demm . . . <br>
<hr>
(src)="65"> Vaccination protects individuals against diseases that could have serious consequences for ... <br>
(trg)="65"> It - tilqim jipproteġi lill - individwi kontra mard li jista ' jkollu konsegwenzi serji għal . . . <br>
<hr>
(src)="66"> Human papillomavirus ( HPV ) infection is a viral infection that is mainly sexually transmitted by direct contact ... <br>
(trg)="66"> Ir - rubella ( il - ħosba Ġermaniża ) hija infezzjoni virali . <br>
<hr>
(src)="67"> Vaccination protects the vaccinated persons and those around them who are vulnerable to the diseases ... <br>
(trg)="67"> It - tilqim jipproteġi lill - persuni mlaqqma u lill - persuni ta ' madwarhom li huma vulnerabbli . . . <br>
<hr>
(src)="68"> When to vaccinate <br>
(trg)="68"> Tagħbija aktar <br>
<hr>
(src)="69"> Vaccines protect people during different stages of life . <br>
(trg)="69"> Il - vaċċini jipproteġu lin - nies matul stadji differenti tal - ħajja . <br>
<hr>
(src)="70"> Vaccines are recommended for different age ... <br>
(trg)="70"> Il - vaċċini huma rakkomandati għal gruppi ta ' etajiet differenti . . . <br>
<hr>
(src)="71"> Before a vaccine can be approved in the EU , it has to undergo rigorous testing by its developer ... <br>
(trg)="71"> Qabel ma vaċċin ikun jista ' jiġi approvat fl - UE , irid jgħaddi minn ittestjar rigoruż mill - iżviluppatur . . . <br>
<hr>
(src)="72"> Trusted sources <br>
(trg)="72"> Aqra iktar <br>
<hr>
(src)="73"> It also provides an overview of the mechanisms in place in the European Union ( EU ) to ensure that available vaccines conform to the highest standards of safety and effectiveness . <br>
(trg)="73"> Dan jipprovdi wkoll ħarsa ġenerali lejn il - mekkaniżmi implimentati fl - Unjoni Ewropea ( UE ) biex jiġi żgurat li l - vaċċini jikkonformaw mal - ogħla standards ta ' sigurtà u effettività . <br>
<hr>
(src)="74"> Measles is a highly contagious viral disease that can be contracted at any age , and that can spread widely . <br>
(trg)="74"> Il - pertussis hija marda batterika infettiva ħafna li tinvolvi l - pulmun u l - passaġġi tan - nifs . <br>
<hr>
(src)="75"> The main purpose of this website is to provide accurate , objective , up-to-date evidence on vaccines and vaccination . <br>
(trg)="75"> L - iskop ewlieni ta ' dan is - sit web huwa li jipprovdi evidenza preċiża , oġġettiva u aġġornata dwar il - vaċċini u t - tilqim . <br>
<hr>
(src)="76"> The main purpose of this website is to provide accurate , objective , up-to-date evidence on vaccines and vaccination in general . <br>
(trg)="76"> F'individwi b'saħħithom din normalment tkun marda ħafifa . <br>
<hr>
(src)="77"> This section provides links to the websites of other health organisations both at national and international level <br>
(trg)="77"> Il - Kummissjoni hija maqsuma f'dipartimenti li jiżviluppaw politiki f'oqsma speċifiċi . <br>
<hr>
(src)="78"> Approval of vaccines in the European Union <br>
(trg)="78"> Approvazzjoni tal - vaċċini fl - Unjoni Ewropea <br>
<hr>
(src)="79"> Safety , quality and standards <br>
(trg)="79"> Sikurezza , kwalità ustandards <br>
<hr>
(src)="80"> Serious side effects are very rare . <br>
(trg)="80"> Effetti sekondarji serji huma rari ħafna . <br>
<hr>
(src)="81"> The last known naturally occurring case was recorded in 1977 in Somalia . <br>
(trg)="81"> L - aħħar każ magħruf li seħħ b'mod naturali ġie rreġistrat fl - 1977 fis - Somalja . <br>
<hr>
(src)="82"> Recently , a vaccine was developed against Ebola virus disease , and research is underway on vaccines to protect against human immunodeficiency virus ( HIV ) . <br>
(trg)="82"> Dan l - aħħar , ġiet żviluppata tilqima kontra l - virus tal - marda tal - Ebola , u qed issir riċerka dwar tilqim li jipproteġu kontra l - virus tal - immunodefiċjenza umana ( HIV ) . <br>
<hr>
(src)="83"> Twitter Facebook Linked In Mail <br>
(trg)="83"> Fatti dwar it - tilqim <br>
<hr>
(src)="84"> The vaccine can only be approved for use in the European Union ( EU ) and European Economic Area ( EEA ) after a scientific evaluation of the results of these tests to ensure its quality , safety and effectiveness . <br>
(trg)="84"> It - tilqima tista ' tiġi approvata biss għall - użu fl - Unjoni Ewropea ( UE ) u ż - Żona Ekonomika Ewropea ( ŻEE ) wara evalwazzjoni xjentifika tar - riżultati ta ' dawn it - testijiet biex tiżgura l - kwalità , is - sikurezza u l - effikaċja tagħha . <br>
<hr>
(src)="85"> Vaccines work by ‘ teaching ' a person 's immune system ( the body 's natural defences ) to defend itself against a specific disease . <br>
(trg)="85"> It - tilqim jaħdem billi ‘ jgħallem ' lis - sistema immunitarja ( id - difiżi naturali tal - ġisem ) biex tiddefendi ruħha kontra marda speċifika . <br>
<hr>
(src)="86"> The vaccine is continuously monitored to ensure it remains safe and effective . <br>
(trg)="86"> It - tilqima tkun qed tiġi ssorveljata kontinwament biex jiġi żgurat li tibqa ' sikura u effettiva . <br>
<hr>
(src)="87"> The first vaccine was developed in the 18th century in the United Kingdom . <br>
(trg)="87"> L - ewwel tilqima ġiet żviluppata fis - seklu 18 fir - Renju Unit . <br>
<hr>
(src)="88"> This evaluation needs to show that a vaccine 's benefits in protecting people against diseases are far greater than any potential risk . <br>
(trg)="88"> Din l - evalwazzjoni teħtieġ turi li l - benefiċċji tat - tilqima fil - protezzjoni tan - nies kontra l - mard humaħafna akbar minn kwalunkwe riskju potenzjali . <br>
<hr>
(src)="89"> The scientific experts evaluating vaccines always consider the benefits and any potential risks very carefully , in particular because vaccines are given to healthy people . <br>
(trg)="89"> L - esperti xjentifiċi li jevalwaw it - tilqim dejjem iqisu l - benefiċċji u kwalunkwe riskju potenzjali b'attenzjoni kbira , b'mod partikolari minħabba tilqim li jingħata lil nies f'saħħithom . <br>
<hr>
(src)="90"> As with any medicine , some people may experience side effects from a vaccine , but these are usually mild and short-lived . <br>
(trg)="90"> Bħal kull mediċina oħra , xi wħud min - nies jistgħu jesperjenzaw effetti sekondarji mit - tilqima , iżda dawn ikunu ġeneralment ħfief u ma jdumux . <br>
<hr>
(src)="91"> Only then , after approval , can a vaccine be manufactured , marketed and used to protect people . <br>
(trg)="91"> B'hekk biss , wara l - approvazzjoni , tista ' tilqima tiġimanifatturata , titqiegħed fis - suq u tintuża biex tipproteġi lin - nies . <br>
<hr>
(src)="92"> Smallpox is now eradicated worldwide in humans thanks to vaccination . <br>
(trg)="92"> Qabel kwalunkwe tilqima ġdida tkun tista ' tintuża , irid isirilha ttestjar rigoruż . <br>
<hr>
(src)="93"> It was a vaccine against smallpox , a deadly disease . <br>
(trg)="93"> Huwa jimmira l - aktar lejn mard ikkawżat minn viruses jew batterji . <br>
<hr>
(src)="94"> They can include mild fever , or pain or redness at the injection site . <br>
(trg)="94"> Il - ġidri , illum il - ġurnatanqerdet mid - dinja kollha fil - bnedmin bis - saħħa tat - tilqim . <br>
<hr>
(src)="95"> They also help to prevent the spread of diseases in the community . <br>
(trg)="95"> Jgħin ukoll fil - prevenzjoni għat - tixrid tal - mard fil - komunità . <br>
<hr>
(src)="96"> vaccinating against humanpapilloma virus ( HPV ) can help prevent cervical and other cancers caused by HPV infection ; <br>
(trg)="96"> it - tilqim kontra l - virus tal - papilloma umana ( HPV ) jista ' jgħin biex jipprevjeni kanċer ċervikali u kanċers oħrajn ikkawżati mill - infezzjoni tal - HPV ; <br>
<hr>
(src)="97"> The connected dots indicate the maximum and minimum number of previously uninfected and unvaccinated people who could get infected by a person with the disease . <br>
(trg)="97"> It - tikek magħqudin jindikaw in - numru massimu u minimu ta ' persuni mhux infettati u mhux imlaqqma preċedentement li jistgħu jiġu infettati minn persuna bil - marda . <br>
<hr>
(src)="98"> 1-4 people <br>
(trg)="98"> L - Influwenza <br>
<hr>
(src)="99"> Source : Plotkin S , Orenstein W , Offit P. Vaccines . <br>
(trg)="99"> Il - programmi tat - tilqim għandhom benefiċċji usa ' għas - soċjetà . <br>
<hr>
(src)="100"> vaccinating against hepatitis B can help prevent liver cancer caused by long-term hepatitis B infection . <br>
(trg)="100"> it - tilqim kontra l - epatite B jista ' jipprevjeni l - kanċer tal - fwied ikkawżat minn infezzjoni tal - epatite B fit - tul . <br>
<hr>
</body>
</html>
